

Table SI. Other cancers

	no. (%)			sex, male – no. (%)						
Patients with ≥ other neoplasm	40 (27,8% ^a)			27 (67,5% ^b)						
	PCFCL*			PCMZL**			PCDLBL			
Patients with other primary skin-cancer – type (no, %)	Previous	Synchronous	Metachronous	Previous	Synchronous	Metachronous	Previous	Synchronous	Metachronous	
Single BCC (n=12, 44,4% ^c)			4	1	2	5				
Multiple BCC (n=7 [£] , 25,9% ^c)		1	5	1		2				
SCC (n=4, 14,8% ^c)			3			1				
Melanoma (n=5, 18,5% ^c)		1	1			2		1		
Plasmocitoma (n=1, 3,7% ^c)				1						
Total (n=27§, 18,8% ^a)	0	2	13	3	2	10	0	1	0	
	PCFCL			PCMZL			PCDLBL			
Patients with other non-skin-related primary cancer – site (no, %)	Previous	Synchronous	Metachronous	Previous	Synchronous	Metachronous	Previous	Synchronous	Metachronous	
CMML (n=1, 6,7% ^d)			1							
Urothelial Cancer (n=3, 20% ^d)	1		1						1	
Prostate Cancer (n=4 26,7% ^d)	1		2			1				
Kidney Cancer (n=1, 6,7% ^d)									1	
Colon Cancer (n=1, 6,7% ^d)				1						
Uterine Cancer (n=1, 6,7% ^d)							1			
Thyroid Cancer (n=, 6,7% ^d)		1								
Breast Cancer (n=2, 13,3% ^d)	1		1							
Laryngeal Cancer (n=1, 6,7% ^d)	1									
Liposarcoma (n=1, 6,7% ^d)							1			
Hodgkin Lymphoma (n=1, 6,7% ^d)	1									
Total (n=15, 10,4% ^a)¶	5	1	5	1	0	1	2	0	2	
	PCFCL			PCMZL			PCDLBL			Total
Therapy approaches undertaken by patients diagnosed with metachronous other primary cancers following PCBCL – no. (%)	Other skin-cancers	Other non-skin-related cancers	Both skin and non-skin cancers	Other skin-cancers	Other non-skin-related cancers	Both skin and non-skin cancers	Other skin-cancers	Other non-skin-related cancers	Both skin and non-skin cancers	(n=31)
Surgery only	3			4						7 (22,6% ^e)
Topical steroids only		2		1						3 (9,7% ^e)
Radiotherapy (RT)	3	3		5				1		12 (38,7% ^e)
Immunosuppressive agents (IA)	5				1					6 (19,4% ^e)
RT+IA	2							1		3 (9,7% ^e)

PCFCL: primary cutaneous follicle-centre cell lymphoma; PCMZL: primary cutaneous marginal zone lymphoma; PCDLBL: primary cutaneous diffuse large B-cell lymphoma; CMML: chronic myelomonocytic leukemia.

Cancers diagnosed six or more months before the diagnosis of PCBCL were considered previous cancer; after six months they were considered metachronous cancer; within six months were considered synchronous primary cancers. ^a Percentages are based on the total number of patients (n=144). ^b Percentages are based on the total number of patients with ≥ other neoplasm (n=40).

^c Percentages are based on the total number of patients with at least one non-lymphoma skin-cancer (n=27).

^d Percentages are based on the total number of patients with at least one non-skin-related primary cancer (n=15).

^e Percentages are based on the total number of other non-lymphoma primary cancers (n=31).

£ 2/7 patients had both metachronous and previous or methachronous and synchronous multiple BCC.

* One patient had both a synchronous skin-cancer and a metachronous skin-cancer.

** One patient had both a previous skin-cancer and a metachronous skin-cancer.

§ Two patients had both BCC and SCC, the number of non-lymphoma skin cancers is 31.

¶ Two patients had two other primary cancers, the number of non-lymphoma non-skin primary cancers is 17.